Literature DB >> 32564156

Options and strategies for hearing restoration in pediatric neurofibromatosis type 2.

Hossein Mahboubi1, William H Slattery1, Gautam U Mehta1, Gregory P Lekovic2.   

Abstract

PURPOSE: In this article, we will review the mechanisms and natural history of hearing loss in neurofibromatosis type 2 (NF2) and discuss the hearing outcomes with different rehabilitation options.
METHODS: Review of the published literature.
RESULTS: NF2 is a rare autosomal dominant syndrome characterized by vestibular schwannomas and other intracranial and spinal tumors. Bilateral vestibular schwannomas are the hallmark of the disease which occur in 90 to 95% of the patients. As a result, hearing loss will eventually occur in almost all NF2 patients. Deafness can occur from tumor progression or from treatment of vestibular schwannomas and is among the most debilitating aspects of NF2. A number of surgical and non-surgical rehabilitation options are available for these patients including cochlear and auditory brainstem implants. The audiologic outcomes with surgical rehabilitation options have been variable but most patients are able to achieve sound awareness and benefit from auditory cues in lip reading.
CONCLUSION: Early identification and treatment of NF2 patients can help in achieving better hearing outcomes in the pediatric population. An increasing number of NF2 patients are receiving open set word understanding with refinement in surgical techniques.

Entities:  

Keywords:  Auditory brainstem implant; Cochlear implant; Deafness; Hearing loss; Neurofibromatosis type 2; Vestibular schwannoma

Mesh:

Year:  2020        PMID: 32564156     DOI: 10.1007/s00381-020-04721-4

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  36 in total

Review 1.  The different forms of neurofibromatosis.

Authors:  M Ruggieri
Journal:  Childs Nerv Syst       Date:  1999-07       Impact factor: 1.475

Review 2.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Authors:  D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

Review 3.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

4.  Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients.

Authors:  Scott R Plotkin; Vanessa L Merker; Alona Muzikansky; Fred G Barker; William Slattery
Journal:  Otol Neurotol       Date:  2014-01       Impact factor: 2.311

5.  Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought.

Authors:  D Gareth R Evans; Anthony Moran; Andrew King; S Saeed; Nihal Gurusinghe; Richard Ramsden
Journal:  Otol Neurotol       Date:  2005-01       Impact factor: 2.311

6.  Neurofibromatosis 2 in the pediatric age group.

Authors:  V F Mautner; M Tatagiba; R Guthoff; M Samii; S M Pulst
Journal:  Neurosurgery       Date:  1993-07       Impact factor: 4.654

7.  Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22.

Authors:  G A Rouleau; W Wertelecki; J L Haines; W J Hobbs; J A Trofatter; B R Seizinger; R L Martuza; D W Superneau; P M Conneally; J F Gusella
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

8.  Empirical development of improved diagnostic criteria for neurofibromatosis 2.

Authors:  Michael E Baser; Jan M Friedman; Harry Joe; Andrew Shenton; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

Review 9.  Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

Authors:  M Ruggieri; A D Praticò; A Serra; L Maiolino; S Cocuzza; P Di Mauro; L Licciardello; P Milone; G Privitera; G Belfiore; M Di Pietro; F Di Raimondo; A Romano; A Chiarenza; M Muglia; A Polizzi; D G Evans
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-10       Impact factor: 2.124

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more
  1 in total

Review 1.  Neurofibromatosis: New Clinical Challenges in the Era of COVID-19.

Authors:  Alessio Ardizzone; Anna Paola Capra; Michela Campolo; Alessia Filippone; Emanuela Esposito; Silvana Briuglia
Journal:  Biomedicines       Date:  2022-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.